Clinical Trial Detail

NCT ID NCT02228096
Title Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

childhood B-cell acute lymphoblastic leukemia

Therapies

Tisagenlecleucel

Age Groups: adult child

No variant requirements are available.